CorMedix (NYSE:CRMD), a Bridgewater, New Jersey-based therapeutic product developer for the prevention and treatment of cardiorenal disease, has added a pharmaceutical veteran to its board of directors.
Matt Duffy has worked for Pfizer (NYSE:PFE) in sales, marketing and product management, and was the first product manager for Viagra. He has led the marketing group at MedImmune where he also oversaw market and product evaluations for the company’s development pipeline. He also presided over the launch of RespiGam and Synagis for the prevention of respiratory disease in premature infants. Synagis sales have exceeded $1 billion, according to a press statement.
Duffy also led commercial operations at Lev Pharmaceuticals where he oversaw launch preparations for Cinrzye, an orphan drug for the treatment of hereditary angioedema. He is currently a managing partner and founder of Black Diamond Research where he provides consulting services to the healthcare industry.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Duffy’s appointment follows some strategic changes at the company earlier this year. In September, Richard M. Cohen, a member of the board of directors, stepped up to serve as the company’s executive chairman in a nonemployee capacity after President and CEO John C. Houghton’s employment agreement was not renewed. Houghton is providing certain transition services on an as-needed basis through the end of 2011, according to a statement from the company at the time.
CorMedix also shifted its focus on the commercialization of Neutrolin to Europe where it expects to secure regulatory approval in the first half of 2012. Getting the CE Mark approval would allow the company to market and sell Neutrolin in 27 countries in the European Union. The company is also reviewing potential strategic alliances with several companies to commercialize Neutrolin in Europe.
